CDHP acts as a competitive inhibitor of the enzyme dihydropyrimidine dehydrogenase (DPD), thereby limiting the degradation of 5-FU and resulting in prolonged, efficacious concentrations of 5-FU in both plasma and tumor tissue (Diasio, 1999; Furuse et al., 2010). The gene discussed is DPYD; the disease is neoplasm.